Hologic (NASDAQ:HOLX) Price Target Lowered to $76.00 at Evercore ISI

Hologic (NASDAQ:HOLX) had its target price cut by Evercore ISI from $78.00 to $76.00 in a report published on Tuesday morning, Benzinga reports. They currently have an in-line rating on the medical equipment provider’s stock.

HOLX has been the subject of several other reports. Citigroup upgraded Hologic from a neutral rating to a buy rating and boosted their price target for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Stephens began coverage on Hologic in a research report on Thursday, June 27th. They set an overweight rating and a $87.00 target price for the company. StockNews.com upgraded Hologic from a hold rating to a buy rating in a research report on Friday, May 3rd. Needham & Company LLC reiterated a buy rating and set a $90.00 target price on shares of Hologic in a research report on Friday, May 3rd. Finally, Argus upped their target price on Hologic from $89.00 to $95.00 and gave the company a buy rating in a research report on Thursday, May 9th. Five analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Hologic currently has a consensus rating of Moderate Buy and a consensus target price of $85.55.

Hologic Stock Down 0.8 %

HOLX stock opened at $73.53 on Tuesday. The company has a current ratio of 3.97, a quick ratio of 3.29 and a debt-to-equity ratio of 0.52. The firm has a market capitalization of $17.16 billion, a PE ratio of 37.52, a PEG ratio of 2.47 and a beta of 0.99. Hologic has a 1-year low of $64.02 and a 1-year high of $82.45. The business’s 50 day simple moving average is $74.21 and its 200 day simple moving average is $74.36.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.98 by $0.05. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The firm’s revenue was down .8% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.06 EPS. As a group, research analysts anticipate that Hologic will post 4.08 EPS for the current year.

Hedge Funds Weigh In On Hologic

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Price T Rowe Associates Inc. MD increased its holdings in Hologic by 77.7% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,297,197 shares of the medical equipment provider’s stock worth $490,931,000 after purchasing an additional 2,753,016 shares in the last quarter. Victory Capital Management Inc. increased its stake in shares of Hologic by 4.5% in the fourth quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider’s stock valued at $361,183,000 after buying an additional 216,958 shares during the period. Norges Bank acquired a new stake in shares of Hologic in the fourth quarter valued at about $217,529,000. BNP PARIBAS ASSET MANAGEMENT Holding S.A. increased its stake in shares of Hologic by 18.3% in the first quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 2,184,427 shares of the medical equipment provider’s stock valued at $170,297,000 after buying an additional 338,212 shares during the period. Finally, The Manufacturers Life Insurance Company increased its stake in shares of Hologic by 117.4% in the fourth quarter. The Manufacturers Life Insurance Company now owns 2,163,718 shares of the medical equipment provider’s stock valued at $154,598,000 after buying an additional 1,168,564 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.